The study designed a multi-epitope peptide vaccine against prostate cancer targeting the biomarkers PSMA, STEAP1 and B7-H3, which are associated with disease progression. They used immunoinformatics for antigen and immunity epitope screening, immune response prediction, HLA allele coverage analysis, molecular docking and molecular dynamics simulations. The selected epitopes were assembled into a vaccine construct with adjuvants and linkers to improve immune activation and stability. The vaccine achieved global coverage of HLA alleles at the level of 97.51%. The construct demonstrated strong binding affinity to B-cell receptors and MHC molecules. Molecular dynamics simulations confirmed favorable structural stability. The results were validated.